LabCorp: Four Deals, One Fee Schedule, and a Stock That Already Voted
A 39% ninety-day run collides with a $125 million PAMA cut — and the most active month of M&A in years
LH · Earnings Call · 2026-10-28
A 39% Run Into the Teeth of a Reimbursement Cut
LabCorp's tape is a single unbroken staircase: the stock is up 39.3% over the last 90 trading days, one continuous up-segment from late June through the 28 October print. That is a market that has decided the diagnostics compounder is back. The quarter gave it cover — revenue of $3.8 billion (+6.9%), organic growth of 5.5%, adjusted operating margin of 15.0% (+60bp), adjusted EPS of $4.78 (+14.5%), and free cash flow of $412 million versus $281 million a year ago. Julia Wang framed the throughline plainly: Q3 was “the sixth consecutive quarter of margin progression across the enterprise” — Julia Wang, Executive Vice President and Chief Financial Officer · 2026-10-28. But the most important number on this call was not a result. It was a price list. CMS's preliminary fee schedule, published in September, would cut Medicare reimbursement for hundreds of lab tests beginning 1 January 2027. Management put the first-year hit at roughly $125 million. That figure has drifted upward: a year ago on this same call, Adam Schechter told investors to “plan that there will be a $100 million impact on both the top line and bottom line for full year 2026” — Adam Schechter, Chairman and Chief Executive Officer · 2025-10-28. The company has now told you, in sequence, that PAMA was a 2026 problem, a deferred problem, and finally a 2027 problem — and the number got bigger, not smaller. The fee schedule is the single freshest keyword in LabCorp's entire vocabulary this quarter, and it arrived at rank two.Three Years of “Strong Pipeline,” Then Four Deals in a Month
The counterweight is M&A, and here the company finally converted talk into paper. Four transactions: MLM Medical Labs (closed, gives LabCorp wholly owned central labs on four continents), plus agreements for select assets of BioReference (~$260 million of revenue, ~$0.15 of adjusted EPS including financing costs, mid-2027 close), Myriad Genetics' prenatal business (~$100 million of revenue, early 2027 close), and Millennium Health. Each is guided to be accretive in year one and to return cost of capital by year three. This is a long-telegraphed promise being cashed. In April, Schechter was still saying “our pipeline for deals is very strong, and it continues to be very strong” — Adam Schechter, Chairman and Chief Executive Officer · 2026-07-30; in July, he conceded the frustration of watching analysts wait. On this call he was almost wry about it: “I have been talking about the strong pipeline for some time now. And, you know, several people said, Adam, you keep talking about it... But when the pipeline is strong, the deals will come” — Adam H. Schechter, Chairman and Chief Executive Officer · 2026-10-28. business development is now the top-ranked keyword for LabCorp, and the Myriad deal and Millennium Health rank alongside it — genuinely new vocabulary replacing quarters of vague pipeline rhetoric. There is a dark symmetry worth naming. PAMA is simultaneously the reason 2027 is hard and the reason the deal pipeline gets easier. Schechter said it directly: smaller hospital and regional labs "are going to struggle a lot with PAMA, and it really does cause them to rethink about their business." The regulation that takes $125 million from LabCorp also hands it acquisition targets at a discount. That is the most interesting sentence on the call, and it was delivered almost as an aside.What Management Quietly Stopped Saying
The tell in the numbers is mix. Diagnostics organic price/mix was 1.3% in Q3 versus 2.5% in Q2, and Schechter pre-emptively defused it: “If you look at any 1 quarter, I would not look at any trend. You are gonna see fluctuations between organic volume and organic price mix quarter over quarter” — Adam H. Schechter, Chairman and Chief Executive Officer · 2026-10-28. Fair — but the mechanical driver, test per accession, is sliding down the keyword hierarchy after dominating the prior quarter, and "price mix" itself appears on the decliner list. What replaced it is mix of a different kind: Wang noted esoteric revenue climbed from 38% to 42% of diagnostic revenue. That is a real, durable shift, and it also happens to be the part of the book that carries higher prices — quietly doing the work that unit pricing no longer does. A genuinely new theme appeared that nobody asked about twice: cardiovascular screening in women. The American College of Cardiology expanded recommendations, and Schechter called cardiovascular disease in women underdiagnosed — before puncturing his own enthusiasm: “when you do 750 million tests per year, it is hard to pull out any type of change like this” — Adam H. Schechter, Chairman and Chief Executive Officer · 2026-10-28. The cardiovascular health keyword is new for LabCorp this quarter and worth watching, but it is a decades-long tailwind, not a 2027 hedge.Does the Balance Sheet Have Room for All This?
Here the tape and the fundamentals start to diverge. The equity has re-rated hard, yet on the last filed quarter the company still traded at just 15.1x operating income — 42% below the 2023Q4 peak of 25.9x. Meanwhile effective net cash of -$5.7 billion leaves little slack, and the deals will be funded from a combination of debt and free cash flow guided to $1.24–1.36 billion for the year. Total revenue is compounding at a mid-single-digit rate; the operating leverage is what is producing the double-digit EPS growth. Which is why the reaffirmed long-term outlook deserves scrutiny. Management is asking investors to believe that launch pad savings, central-lab momentum (book-to-bill 1.13 in the quarter, 1.10 trailing twelve months, backlog $8.9 billion), deal accretion, and underlying diagnostics volume can together absorb $125 million — after already absorbing it in the plan. Schechter was more candid than most CEOs would be:That is a guided-up company admitting front-loaded pain. The 90-day tape has already priced the easing; it has not yet priced the trough.Obviously, we will wait to see what happens with PAMA and the RESULTS Act... But, obviously, the year that PAMA is implemented will be a tougher year than the other years. It will get easier after the PAMA years.